scholarly journals The relationship between hardiness, quality of life and cardiovascular risk factors in law enforcement officers

2000 ◽  
Author(s):  
Deanna Lee Greving
Author(s):  
João Vítor Costa dos Santos Chaves ◽  
Keila Lindineia Silva Pinto ◽  
Kleicillainy Mota de Sousa ◽  
Lucas Oliveira Soares ◽  
André Luiz Lisboa Cordeiro

2019 ◽  
Vol 32 (8) ◽  
pp. 871-877 ◽  
Author(s):  
Roopa Vijayan ◽  
Nisha Bhavani ◽  
Praveen V. Pavithran ◽  
Vasantha Nair ◽  
Usha V. Menon ◽  
...  

Abstract Background The present study was designed to evaluate the metabolic profile, cardiovascular risk factors and quality of life in children with congenital adrenal hyperplasia (CAH) and compare it with age- and sex-matched controls. Methods Fifty-two patients aged 3–21 years with classic CAH due to 21-hydroxylase deficiency were included in the study. Metabolic profiling was done for 36 cases and compared with 28 healthy age- and sex-matched controls. Quality of life was assessed in all 52 children and their parents using a validated Pediatric Quality of Life Inventory (PedsQL) questionnaire and was compared with normative data from the same population. Results The median age was 12 years with 14 (27%) males and 38 (73%) females. Out of the total 52 patients, 35 (67%) had salt wasting and 17 (33%) had simple virilising CAH. The median height standard deviation score (SDS) of cases was similar to that of controls (−0.72 vs. −0.64, p = 0.57) and 81% of females had normal pubertal status indicating a good control of the disease. Weight SDS, body mass index (BMI) SDS, mean diastolic blood pressure and insulin resistance were significantly higher in cases when compared to controls (0.31 vs. −0.3; 0.96 vs. 0.17; 67.8 ± 10.49 vs. 61 ± 8.49 and 2.1 vs. 0.95, respectively). The quality of life was significantly reduced in all domains as per parents’ perspective, whereas the children reported reduced quality of social and school functioning. There was no significant correlation between quality of life and metabolic parameters. Conclusions Children with CAH despite a reasonably good control of the disease have a higher cardiovascular risk and reduced quality of life when compared to healthy controls.


Clinics ◽  
2008 ◽  
Vol 63 (6) ◽  
Author(s):  
Luiz Mário Baptista Martinelli ◽  
Bruno Moreira Mizutani ◽  
Anibal Mutti ◽  
Maria Paula Barbieri D'elia ◽  
Rodrigo Soler Coltro ◽  
...  

2019 ◽  
pp. 1357633X1988579 ◽  
Author(s):  
Johan A Snoek ◽  
Esther P Meindersma ◽  
Leonie F Prins ◽  
Arnoud WJ van’t Hof ◽  
Menko-Jan de Boer ◽  
...  

Introduction The aim of this study was to assess the acute and sustained effects of a six-month heart-rate-based telerehabilitation programme, following the completion of cardiac rehabilitation (CR), on peak oxygen uptake (peakVO2), quality of life (QoL), cardiovascular risk factors and care utilisation in patients with coronary artery disease (CAD). Methods A total of 122 patients with CAD were randomised, after the completion of CR, to an intervention group with six months of telemonitoring and telecoaching (TELE) or a control group with a traditional six-month follow-up programme with monthly calls (CON). The primary outcome was peakVO2 at 12 months, to assess the sustained effects of TELE. The secondary outcomes included QoL, cardiovascular risk factors (lipid spectrum), major adverse cardiovascular events (MACE) and habitual physical activity. Results PeakVO2 increased significantly from baseline to 12 months in TELE (+2.5 mL·kg−1min−1 (95% CI 1.5–3.2)) and CON (+1.9 mL·kg−1min−1 (95% CI 1.0–2.5)), and did not differ between groups (P = 0.28). Similarly, QoL (P = 0.31), total cholesterol (P = 0.45), MACE (P = 0.86) did not differ between groups and in time. Discussion Extending CR with a heart-rate-based telerehabilitation programme did not yield additional sustainable health benefits compared with regular care with monthly telephone calls. These observations highlight that both telerehabilitation and regular care with monthly telephone calls may prevent the typically observed reductions in peakVO2 following the completion of a CR programme.Trial registration: Dutch Trial Register NL4140 (registered 6 December 2014)


2011 ◽  
Vol 155 (5) ◽  
pp. 281 ◽  
Author(s):  
Torgeir T. Søvik ◽  
Erlend T. Aasheim ◽  
Osama Taha ◽  
My Engström ◽  
Morten W. Fagerland ◽  
...  

2020 ◽  
Author(s):  
Jalal Moludi ◽  
Hamed Khedmatgozar ◽  
Fatemeh Pourteymour Fard Tabrizi ◽  
Hamidreza Razmi ◽  
Mehdi Amirpour ◽  
...  

Abstract Objective: Studies have proposed a link between psoriasis and an imbalanced gut microbiome. Therefore, the modulation of the gut microbiota with probiotics may improve clinical outcomes, metabolic endotoxemia, chronic inflammation, and cardiovascular risk factors in patients with psoriasis.Methods: Forty-six patients with psoriasis randomized into two groups, group 1 received a twice a day capsule having freeze-dried powder with 1.6×109 CFU for eight weeks, and group 2 received placebo. For clinical outcomes, we used the Psoriasis Area and Severity Index (PASI), blood pressure, and SF36 to measure the quality of life. And for biochemistry analysis, we measured pro-inflammatory cytokines (hs-CRP and IL1-β), lipopolysaccharides (LPS), and lipid profile. All the data collected at baseline and the end of the study. Results: Forty-six patients (28 [60%] female; mean [SD] age, 42.51 [14.55] years) contributed to the study. Improvements in SF36 score as an indexed for the QOL was significant in patients taking probiotics supplementation comparing to the placebo group and PASI (-5.06±2.10 vs. 0.30±1.80, P=0.049) as well. After the intervention, the treatment group had significant reductions in LDL and TC compared to the placebo group. In addition, we observed a considerable reduction in serum LPS levels (-7.21±10.33 vs. -2.74±0.97 mmol/L, P=0.010), hs-CRP levels (-1.67 ±0.95 vs. -0.70+ 0.38 mg/L, P=0.013), and IL1- β levels (-1.64 ±1.10 vs. 0.17+ -0.20 mg/L, P=0.043) in the probiotics group. Conclusion: This study shows that probiotics significantly improved the quality of life and seriousness in psoriatic patients. Moreover, it enhances cardiovascular risk factors and inflammatory/oxidative stress markers. Trial registration: This trial also was recorded in the Iranian registry of clinical trials (https://www.irct.ir) (code: IRCT20191124045483N1).


Sign in / Sign up

Export Citation Format

Share Document